Literature DB >> 35368633

Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor-Associated Acute Kidney Injury: PRO.

Mark Eijgelsheim1, Ben Sprangers2,3.   

Abstract

Entities:  

Keywords:  Clinical Nephrology; Glomerular and Tubulointerstitial Diseases; checkpoint inhibitors; interstitial nephritis; kidney biopsy; onconephrology

Mesh：

Substances：

Year:  2020        PMID： 35368633      PMCID： PMC8809263          DOI： 10.34067/KID.0001192019

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  19 in total

1.  AKI in Patients Receiving Immune Checkpoint Inhibitors.

Authors:  Mark A Perazella; Ben Sprangers
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-02       Impact factor: 8.237

Review 2.  Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review.

Authors:  Rimda Wanchoo; Sabine Karam; Nupur N Uppal; Valerie S Barta; Gilbert Deray; Craig Devoe; Vincent Launay-Vacher; Kenar D Jhaveri
Journal:  Am J Nephrol       Date:  2017-01-12       Impact factor: 3.754

3.  Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis.

Authors:  Dennis G Moledina; F Perry Wilson; Jordan S Pober; Mark A Perazella; Nikhil Singh; Randy L Luciano; Wassim Obeid; Haiqun Lin; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Lloyd G Cantley; Chirag R Parikh
Journal:  JCI Insight       Date:  2019-05-16

4.  Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.

Authors:  Troy Z Horvat; Nelly G Adel; Thu-Oanh Dang; Parisa Momtaz; Michael A Postow; Margaret K Callahan; Richard D Carvajal; Mark A Dickson; Sandra P D'Angelo; Kaitlin M Woo; Katherine S Panageas; Jedd D Wolchok; Paul B Chapman
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

5.  Durable response after discontinuation of nivolumab therapy in the absence of disease progression or toxicity with two advanced NSCLC patients.

Authors:  Mesut Yilmaz; Sermin Guven Mese
Journal:  J Oncol Pharm Pract       Date:  2019-08-18       Impact factor: 1.809

6.  Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study.

Authors:  Akbar K Waljee; Mary A M Rogers; Paul Lin; Amit G Singal; Joshua D Stein; Rory M Marks; John Z Ayanian; Brahmajee K Nallamothu
Journal:  BMJ       Date:  2017-04-12

7.  Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.

Authors:  Omar Mamlouk; Umut Selamet; Shana Machado; Maen Abdelrahim; William F Glass; Amanda Tchakarov; Lillian Gaber; Amit Lahoti; Biruh Workeneh; Sheldon Chen; Jamie Lin; Noha Abdel-Wahab; Jean Tayar; Huifang Lu; Maria Suarez-Almazor; Nizar Tannir; Cassian Yee; Adi Diab; Ala Abudayyeh
Journal:  J Immunother Cancer       Date:  2019-01-06       Impact factor: 13.751

8.  Renal toxicities associated with pembrolizumab.

Authors:  Hassan Izzedine; Alexis Mathian; Stephane Champiat; Cécile Picard; Christine Mateus; Emilie Routier; Andrea Varga; David Malka; Alexandra Leary; Judith Michels; Jean-Marie Michot; Aurélien Marabelle; Olivier Lambotte; Zahir Amoura; Jean-Charles Soria; Sihem Kaaki; Nathalie Quellard; Jean-Michel Goujon; Isabelle Brocheriou
Journal:  Clin Kidney J       Date:  2018-11-09

9.  Anti-PD-1 Immunotherapy May Induce Interstitial Nephritis With Increased Tubular Epithelial Expression of PD-L1.

Authors:  Clarissa Cassol; Anjali Satoskar; Gerard Lozanski; Brad Rovin; Lee Hebert; Tibor Nadasdy; Sergey V Brodsky
Journal:  Kidney Int Rep       Date:  2019-06-20

10.  Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.

Authors:  Emilien Billon; Jochen Walz; Serge Brunelle; Jeanne Thomassin; Naji Salem; Mathilde Guerin; Cecile Vicier; Slimane Dermeche; Laurence Albiges; Florence Tantot; Soazig Nenan; Geraldine Pignot; Gwenaëlle Gravis
Journal:  Front Oncol       Date:  2019-10-09       Impact factor: 6.244
View more
  4 in total

Review 1.  Treatment of acute kidney injury in cancer patients.

Authors:  Pauline Braet; Giulia Vanessa Re Sartò; Marta Pirovano; Ben Sprangers; Laura Cosmai
Journal:  Clin Kidney J       Date:  2021-12-24

Review 2.  Adverse Renal Effects of Anticancer Immunotherapy: A Review.

Authors:  Maciej Borówka; Stanisław Łącki-Zynzeling; Michał Nicze; Sylwia Kozak; Jerzy Chudek
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

Review 3.  Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

Authors:  Sheila Bermejo; Mónica Bolufer; Mar Riveiro-Barciela; Maria José Soler
Journal:  Front Med (Lausanne)       Date:  2022-06-14

4.  'Prevention is better than cure': warning for comedications in patients receiving immune checkpoint inhibitors to avoid acute kidney injury.

Authors:  Julie Belliere; Ben Sprangers
Journal:  Clin Kidney J       Date:  2022-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.